Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-10-04 Gibson Christopher Chief Executive Officer Exercise or conversion +31,250 $2.48 $78K 902,541
2023-10-04 Gibson Christopher Chief Executive Officer Sale −59,794 $7.21 $431K 842,747
2023-10-04 Gibson Christopher Chief Executive Officer Exercise or conversion · Stock Option (Right to Buy) −31,250 468,750
2023-10-03 Borgeson Blake Director Sale −8,885 $7.29 $65K 7,434,075
2023-10-02 Dar Zavain Director Grant or award +1,920 73,964
2023-10-02 CHAVEZ R. MARTIN Director Grant or award +2,619 56,177
2023-10-02 Li Dean Y Director Grant or award +1,659 1,326,415
2023-09-28 Larson Tina Marriott President and COO Exercise or conversion 10b5-1 +3,000 $1.06 $3K 421,782
2023-09-28 Larson Tina Marriott President and COO Sale 10b5-1 −3,000 $7.72 $23K 418,782
2023-09-28 Larson Tina Marriott President and COO Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −3,000 526,000
2023-09-19 Borgeson Blake Director Sale −8,885 $8.36 $74K 7,442,960
2023-09-15 Virani Shafique Chief Business Officer Exercise or conversion 10b5-1 +18,000 $2.22 $40K 158,351
2023-09-15 Virani Shafique Chief Business Officer Sale 10b5-1 −18,000 $8.66 $156K 140,351
2023-09-15 Virani Shafique Chief Business Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −18,000 433,469
2023-09-15 Gibson Christopher Chief Executive Officer Conversion +10,000 881,291
2023-09-15 Gibson Christopher Chief Executive Officer Gift −10,000 871,291
2023-09-15 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −10,000 6,511,496
2023-09-13 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +37,500 $2.22 $83K 913,186
2023-09-13 Secora Michael Chief Financial Officer Sale 10b5-1 −25,000 $8.69 $217K 888,186
2023-09-13 Secora Michael Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −37,500 1,335,135

Page 31 of 41 · 805 trades